Company: Neurimmune Therapeutics
Drug Type: Protein Biologic
Conditions: ALS, frontotemporal dementia, Alzheimer’s disease
Mechanism Type: Protein aggregate clearance, TDP-43
Mechanism: NI-205 is a human-derived monoclonal antibody that targets TDP-43. Pathological cytoplasmic aggregates of TDP-43 are a hallmark of ALS and ALS/frontotemporal dementia, and mutations in the gene are associated with both diseases.
U.S. Status for ALS: Preclinical
 Neurimmune – Product Pipeline. Neurimmune. Product Pipeline. Accessed 11 Mar 2016 from http://www.neurimmune.com/products/product-pipeline.html
 NeurImmune allies with Biogen. European Biotechnology. NeurImmune allies with Biogen. 2 Jun 2011. Accessed 11 Mar 2016 from http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/9/article/neurimmune-allies-with-biogen.html.
Last updated March 11th, 2016